ck1

CK1-IN-3 is casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases.

CK1-IN-1 (PUN51207) is a casein kinase 1 (CK1) inhibitor. CK1-IN-1 has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.

CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

Epiblastin A is an inhibitor of Casein Kinase 1 (CK1). Epiblastin A engages CK1 isoenzymes in cell lysate and induces efficient conversion of epiblast stem cells (EpiSCs) into embryonic stem cells (cESCs).

AMG-548 is a selective and orally active p38α MAPK inhibitor (Ki = 0.5 nM), with higher selectivity than p38β, p38γ, and p38δ, and can also inhibit the TNFα, CK1δ/ε, and Wnt signalling pathways.

CKI-7 free base is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor, also inhibiting SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

SSTC3 is a casein kinase 1α (CK1α) activator and a potent HIF1α inhibitor, each with a Kd of 32 nM. It has potential antitumor activity, inhibits WNT signaling, and suppresses SHH medulloblastoma tumor growth.

LH846 is a selective inhibitor of CK1δ with IC50 values of 290 nM for CK1δ, 1.3 μM for CK1ε, and 2.5 μM for CK1α, and exhibits no inhibitory activity at CK2.

JW 67 is an inhibitor of canonical Wnt pathway signaling. JW 67 rapidly reduced active β-catenin with a subsequent downregulation of Wnt target genes, including AXIN2, SP5, and NKD1.

IC261 (SU-5607) is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.

D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).

Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers.

VRK1/CK1-IN-1 (compound 36) is a dual inhibitor targeting vaccinia-related kinase 1 (VRK1) and casein kinase 1 (CK1), with a Ki of 37.9 nM for VRK1. It exhibits IC50 values of 17 nM and 15 nM for CK1 δ and ε isoforms, respectively.

CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with IC50 values of 123, 19.8, 26.8, and 74.3 nM for CK1a, CK1d, CK1e, and p38a, respectively, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy.

CK1-IN-4 (Compound 59) is an inhibitor of casein kinase CK1δ with an IC50 of 2.74 μM. It exhibits neuroprotective activity in SH-SY5Y cells treated with Ethacrynic acid.

CK1-IN-2 (compound Nr.4) hydrochloride is an effective inhibitor of CK1, exhibiting inhibitory IC50 values of 123 nM, 19.8 nM, 26.8 nM, and 74.3 nM against CK1a, CK1d, CK1e, and p38a respectively.

CK1δ CK1ε ligand-1 is a ligand of CK1δ CK1ε and can serve as a target protein ligand for the synthesis of the CK1 PROTAC degrader AH078.

CK1δ-IN-10 (Compound 85) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ (CSNKID), with an IC50 value of 0.255 μM.

CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.

CK1tide serves as a substrate for Casein Kinase 1 (CK1), allowing for the assessment of CK1's catalytic activity in vitro by determining its ability to phosphorylate CK1tide.

CCK1-specific peptide substrate is a bioactive peptide. [The peptide sequence is based on Ser7-phosphorylated rabbit muscle glycogen synthase.] It serves as a peptide substrate for casein kinase I (CK1), which phosphorylates Ser10. In vivo, Ser7 is phosphorylated by PKA.